Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Ovarian tissue cryopreservation in girls and adolescents at risk of gonadotoxicity: a 15-year experience in 159 patients from a referral program.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report a 15-year single-center experience of a pediatric fertility preservation program based on ovarian tissue cryopreservation (OTC), focusing on patient selection, program logistics, and endocrine and reproductive outcomes with explicit consideration of age- and treatment-related evaluability. METHODS/PATIENTS: Retrospective observational study including all girls and adolescents who underwent OTC between 2010 and 2025. Eligibility was based on structured gonadotoxic risk assessment integrating diagnosis, alkylating-agent exposure, radiotherapy fields/doses, and hematopoietic stem cell transplantation (HSCT). Outcomes were analyzed descriptively. Ovarian function was assessed in patients considered evaluable at last follow-up (aged ≥ 13 years, off treatment, and with endocrine follow-up available).
resultsA total of 159 patients underwent OTC (median age at OTC 11.0 years). Malignant diseases accounted for 131/159 (82.3%), including leukemias/lymphoblastic lymphomas 35/159 (22.0%) managed in the context of HSCT, and other malignancies 96/159 (60.4%); non-malignant conditions accounted for 28/159 (17.7%). OTC was coordinated with another procedure under anesthesia in 106/159 (66.6%), and ovarian transposition was performed in 27/159 (17.0%) when abdominal and/or pelvic radiotherapy represented the main gonadotoxic risk. Among patients evaluable for ovarian function (n = 83), primary ovarian insufficiency was diagnosed in 36/83 (43.4%) (36/159, 22.6% overall); hormone replacement therapy was administered in 31/36 (86.1%).
conclusionA structured, risk-based OTC program can be integrated into pediatric oncology care with close logistical coordination. Clear definition of evaluability denominators and long-term multidisciplinary follow-up are essential for accurate interpretation of endocrine outcomes in this high-risk population.
Indexed as
Identifiers
41991899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.